Alcresta Launches With Dynamic Business Model; Raises $10M Series A
This article was originally published in The Pink Sheet Daily
Executive Summary
Former Alnara executives have come together with the company’s previous investors to launch two start-ups focusing on enzyme therapies.
You may also be interested in...
Alnara Execs Start Anew With Allena; $15 M Series A
Former Alnara founders Alexey Margolin and Robert Gallotto have begun a new venture that includes Alnara’s previous investors.
Lilly To Buy Alnara And Its Non-Porcine Pancreatic Enzyme Replacement Therapy
Alnara hopes to leverage Lilly's prior success with recombinant insulin products.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.